Overall,CD19-SynNotch PDbody-CAR T cells represent a distinct developmentover previously published designs due to their increased efficacy,proliferative capability, and mitigation of off-tumor toxicity forsolid tumor treatment. The gene discussed is CD19; the disease is neoplasm.